In this randomized double-blinded case-control clinical trial study, 60 patients with Bronchiectasis who referred to Pulmonary Subspecialty Clinic of Razi Hospital from March 2017 to March 2018 will be enrolled. The patients will be male or females above 18 years old who fulfilled the inclusion and exclusion criteria of the study. After obtaining an informed consent from the subjects, they will be randomly categorized in either the intervention (group A) or the control group (group B).
At the beginning of the trial, study variables including the patients' demographic features (age, weight, height) will be recorded. Also, a sputum culture will be obtained and a primary spirometry will be performed. Furthermore, histories of exacerbations of the disease in the same time-period in the last two years will be asked and recorded. To perform the study, the patients in both groups will be treated for their underlying disease, with the intervention group taking additional Lactocare probiotic. This joint formula contains high amounts of seven "helpful" bacterial species, including Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium berve, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus acidophilus, Streptococcus thermophilus, together with Fructooligosaccharides probiotic in forms of capsules. These capsules and their placebos are prescribed twice a day for six months. The patients will be visited in the same clinic every month and their clinical manifestations and possible exacerbations will be recorded. At the end of the six-month period, the results of sputum cultures and patients' weight will be evaluated and a second spirometry will be performed. These clinical findings will also be compared with the same time period of last year by asking the patients about them. Finally, the data will be compared and analyzed